IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v590y2021i7845d10.1038_s41586-020-3035-9.html
   My bibliography  Save this article

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

Author

Listed:
  • Lorena Sanchez-Felipe

    (KU Leuven
    Global Virus Network (GVN))

  • Thomas Vercruysse

    (KU Leuven
    KU Leuven)

  • Sapna Sharma

    (KU Leuven
    Global Virus Network (GVN))

  • Ji Ma

    (KU Leuven
    Global Virus Network (GVN))

  • Viktor Lemmens

    (KU Leuven
    Global Virus Network (GVN))

  • Dominique Van Looveren

    (KU Leuven
    KU Leuven)

  • Mahadesh Prasad Arkalagud Javarappa

    (KU Leuven
    Global Virus Network (GVN))

  • Robbert Boudewijns

    (KU Leuven
    Global Virus Network (GVN))

  • Bert Malengier-Devlies

    (KU Leuven)

  • Laurens Liesenborghs

    (KU Leuven
    Global Virus Network (GVN))

  • Suzanne J. F. Kaptein

    (KU Leuven
    Global Virus Network (GVN))

  • Carolien De Keyzer

    (KU Leuven
    Global Virus Network (GVN))

  • Lindsey Bervoets

    (KU Leuven
    Global Virus Network (GVN))

  • Sarah Debaveye

    (KU Leuven
    Global Virus Network (GVN))

  • Madina Rasulova

    (KU Leuven
    KU Leuven)

  • Laura Seldeslachts

    (KU Leuven)

  • Li-Hsin Li

    (KU Leuven
    Global Virus Network (GVN))

  • Sander Jansen

    (KU Leuven
    Global Virus Network (GVN))

  • Michael Bright Yakass

    (KU Leuven
    Global Virus Network (GVN)
    University of Ghana)

  • Babs E. Verstrepen

    (Biomedical Primate Research Centre (BPRC))

  • Kinga P. Böszörményi

    (Biomedical Primate Research Centre (BPRC))

  • Gwendoline Kiemenyi-Kayere

    (Biomedical Primate Research Centre (BPRC))

  • Nikki van Driel

    (Biomedical Primate Research Centre (BPRC))

  • Osbourne Quaye

    (Global Virus Network (GVN)
    University of Ghana)

  • Xin Zhang

    (KU Leuven
    Global Virus Network (GVN))

  • Sebastiaan ter Horst

    (KU Leuven
    Global Virus Network (GVN))

  • Niraj Mishra

    (KU Leuven
    Global Virus Network (GVN)
    Gene Therapy Division, Intas Pharmaceuticals)

  • Ward Deboutte

    (KU Leuven)

  • Jelle Matthijnssens

    (KU Leuven)

  • Lotte Coelmont

    (KU Leuven
    Global Virus Network (GVN))

  • Corinne Vandermeulen

    (Leuven University Vaccinology Center (LUVAC), KU Leuven
    KU Keuven)

  • Elisabeth Heylen

    (KU Leuven)

  • Valentijn Vergote

    (KU Leuven)

  • Dominique Schols

    (KU Leuven)

  • Zhongde Wang

    (Utah State University)

  • Willy Bogers

    (Biomedical Primate Research Centre (BPRC))

  • Thijs Kuiken

    (Erasmus University Medical Center)

  • Ernst Verschoor

    (Biomedical Primate Research Centre (BPRC))

  • Christopher Cawthorne

    (KU Leuven)

  • Koen Van Laere

    (KU Leuven)

  • Ghislain Opdenakker

    (KU Leuven)

  • Greetje Vande Velde

    (KU Leuven)

  • Birgit Weynand

    (Translational Cell and Tissue Research, KU Leuven)

  • Dirk E. Teuwen

    (KU Leuven)

  • Patrick Matthys

    (KU Leuven)

  • Johan Neyts

    (KU Leuven
    Global Virus Network (GVN))

  • Hendrik Thibaut

    (KU Leuven
    KU Leuven)

  • Kai Dallmeier

    (KU Leuven
    Global Virus Network (GVN))

Abstract

The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are being leveraged for a rapid emergency response1. Here we describe the development of a candidate vaccine (YF-S0) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express a noncleavable prefusion form of the SARS-CoV-2 spike antigen. We assess vaccine safety, immunogenicity and efficacy in several animal models. YF-S0 has an excellent safety profile and induces high levels of SARS-CoV-2 neutralizing antibodies in hamsters (Mesocricetus auratus), mice (Mus musculus) and cynomolgus macaques (Macaca fascicularis), and—concomitantly—protective immunity against yellow fever virus. Humoral immunity is complemented by a cellular immune response with favourable T helper 1 polarization, as profiled in mice. In a hamster model2 and in macaques, YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose conferred protection from lung disease in most of the vaccinated hamsters within as little as 10 days. Taken together, the quality of the immune responses triggered and the rapid kinetics by which protective immunity can be attained after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.

Suggested Citation

  • Lorena Sanchez-Felipe & Thomas Vercruysse & Sapna Sharma & Ji Ma & Viktor Lemmens & Dominique Van Looveren & Mahadesh Prasad Arkalagud Javarappa & Robbert Boudewijns & Bert Malengier-Devlies & Laurens, 2021. "A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate," Nature, Nature, vol. 590(7845), pages 320-325, February.
    • Handle: RePEc:nat:nature:v:590:y:2021:i:7845:d:10.1038_s41586-020-3035-9
    DOI: 10.1038/s41586-020-3035-9
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-020-3035-9
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/s41586-020-3035-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Sapna Sharma & Thomas Vercruysse & Lorena Sanchez-Felipe & Winnie Kerstens & Madina Rasulova & Lindsey Bervoets & Carolien Keyzer & Rana Abdelnabi & Caroline S. Foo & Viktor Lemmens & Dominique Loover, 2022. "Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters," Nature Communications, Nature, vol. 13(1), pages 1-11, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:590:y:2021:i:7845:d:10.1038_s41586-020-3035-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.